HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

FDA approves tirzepatide for CV risk reduction in type 2 diabetes after SURPASS-CVOT

Louis Nervegna · Aug 28, 2026 · ♥ 5 reactions · 3 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Heart attack, stroke & proceduresInsulin resistance & diabetes
AI summary & key facts

Louis shares that the FDA approved tirzepatide to lower heart attack and stroke risk in type 2 diabetes, based on SURPASS-CVOT. In 13,299 adults with established heart disease, tirzepatide was noninferior to dulaglutide for MACE (12.2% vs 13.1%, HR 0.92), without formally reaching superiority.

The FDA just approved tirzepatide to lower the risk of heart attack and stroke in people with type 2 diabetes.

This approval is based on strong results from the SURPASS-CVOT clinical trial.

#tirzepetideHD #glp1HD #surpasscvotHD #dulaglutideHD

Research cited

The approval rests on SURPASS-CVOT, the first heart outcome trial to test an incretin drug against another active cardioprotective drug instead of placebo.

The trial

Headline result

✅ Noninferiority met (P=0.003)
❌ Superiority not formally reached (P=0.09), but every MACE component trended in tirzepatide’s favor

Why noninferiority still matters

Supporting data

Safety: consistent with the #GLP class — mainly more GI effects (nausea, diarrhea, vomiting)

Bottom line: Tirzepatide now has robust evidence for heart protection in T2D + ASCVD, not just glucose and weight benefits.

📚 References

  1. Cardiovascular Outcomes with Tirzepatide vs Dulaglutide in T2D. N Engl J Med. 2025;393(24):2409-2420.
  2. Tirzepatide and Cardioprotection in T2D: Insights From SURPASS-CVOT. Diabetes Obes Metab. 2026;28(7):5413-5415.
  3. Cardiorenal Outcomes With Tirzepatide vs Dulaglutide.
  4. Indirect comparison analysis (SURPASS-CVOT + REWIND).
  5. SURPASS-4 trial.
  6. Meta-analysis of 7 SURPASS trials.
  7. 2026 real-world cohort (sitagliptin comparator).

#Tirzepatide #Mounjaro #heart #diabetes

← newer: Choline and phosphatidylcholine decline may drive age-relateolder: Shingrix linked to 24% lower dementia risk in over 500,000 M →